PharmaFocus Today – Page 43 – media

Zelgen Pharmaceuticals’ ZG006 for injection in combination with PD-1/PD-L1 immune checkpoint inhibitors approved for clinical trials

On the evening of April 20, Zejing Pharmaceutical announced that the combination of ZG006 for injection and PD-1/PD-L1 immune checkpoint inhibitors has obtained the approval notice for drug clinical trials. The announcement shows that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the National Medical Products Administration, and the clinical trial of ZG006 for injection combined with PD-1/PD-L1 immune checkpoint inhibitors for small cell lung cancer has been approved. The announcement shows that ZG006 for injection is a trispecific antibody drug developed by the company and its subsidiary Gensun Biopharma Inc. through its bi-/multi-specific antibody research and development platform. The drug has obtained clinical trial approval from both the U.S. FDA and China’s NMPA, and has been granted orphan drug status by the U.S. FDA. https://finance.eastmoney.com/a/202504213382407847.html
- Source: drugdu
- 140
- April 23, 2025
EU approves first Alzheimer’s drug

Recently, Biogen and Eisai jointly announced that the European Commission has officially approved their anti-amyloid β antibody drug Lecanemab for marketing for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer’s disease (AD) in adult patients. This indication is limited to apolipoprotein Eε4 (ApoEε4) non-carriers or heterozygotes, and patients must be diagnosed with evidence of amyloid pathology. Back in July 2024, the European Medicines Agency gave a “not recommended” opinion on Lecanemab’s marketing application due to its benefit-risk ratio. After the research and development team supplemented additional data and the regulatory agency re-evaluated it, the drug was finally approved and became the first therapeutic drug in the EU for the potential cause of Alzheimer’s disease. The road to counterattack Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that can selectively neutralize and remove soluble toxic Aβ aggregates that cause AD neuropathy, thereby positively affecting the AD ...
- Source: drugdu
- 98
- April 23, 2025
Innovent Biologics’ Zoletinib tablets are on the market, ushering in a new breakthrough in China’s anti-cancer efforts

Recently, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that the NDA for Zurletrectinib (R&D code ICP-723), a Class 1 anti-tumor new drug independently developed by Innovent Biologics, has been accepted. The drug is a second-generation pan-TRK inhibitor, intended for the treatment of adult and adolescent patients (12 years old ≤ age < 18 years old) with advanced solid tumors carrying NTRK fusion genes, marking an important progress in China’s “unlimited cancer” targeted therapy field. Zolotinib is a new generation of pan-TRK inhibitor. Its core advantage lies in its ability to effectively solve the drug resistance problem of the first-generation TRK inhibitors (such as larotrectinib and entrectinib). According to the key registration Phase II clinical trial data disclosed in InnoCare Pharma’s 2024 annual report, the drug showed excellent efficacy in patients with NTRK fusion-positive advanced solid tumors, with an overall ...
- Source: drugdu
- 86
- April 23, 2025
Confident in the future performance of the overseas medical beauty market

Huadong Medicine (000963) issued an announcement that the company held an annual performance exchange meeting on April 18, 2025. The company said that it is actively preparing for the listing of Ailahe® and will actively participate in medical insurance negotiations to strive to enter medical insurance as soon as possible. Bailing Capsules were successfully selected in the national Chinese patent medicine alliance centralized procurement renewal at the end of last year. The winning price adjustment was relatively small. While ensuring the coverage of the core market, it also laid the foundation for subsequent grassroots penetration. The oral small molecule GLP-1 receptor agonist HDM1002 study achieved the preset test goals, has a good weight loss effect, and has good safety and tolerability. The first subject has been enrolled in the Phase III clinical study of weight management indications. The company’s semaglutide injection diabetes indication has been submitted for listing in March ...
- Source: drugdu
- 120
- April 22, 2025
HRS-1167 tablets clinical trial approved

On April 20, the company announced that HRS-1167 tablets obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration and will conduct clinical trials in the near future. HRS-1167 tablets are highly selective, highly active, and orally available PARP1 small molecule inhibitors independently developed by the company with intellectual property rights. They belong to the second generation of PARP inhibitors. Compared with the first generation of PARP inhibitors, HRS-1167 has higher selectivity and stronger affinity for PARP1. HRS-1167 is currently in the early clinical development stage and has the potential to be used as a monotherapy and combination therapy to treat more patients, including tumor patients who were previously unable to use PARP inhibitors. Upon inquiry, no similar products have been approved for marketing at home and abroad. As of now, the R&D expenses of HRS-1167 tablets related projects have accumulated to approximately RMB 72.11 million. ...
- Source: drugdu
- 199
- April 22, 2025
Watson Bio’s 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials

On April 18, Watson Bio (300142) issued an announcement that the 20-valent pneumococcal polysaccharide conjugate vaccine jointly applied for clinical trials by the company and its subsidiaries has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, with the notice number: 2025LP01099. The clinical trial of this vaccine will target children aged 2 months (minimum 6 weeks old) to 5 years old to prevent infectious diseases caused by the 20 pneumococcal serotypes contained in this product. This vaccine is an iterative upgrade based on the company’s already marketed 13-valent pneumococcal polysaccharide conjugate vaccine, with 7 new serotypes added. At present, only Pfizer in the United States has launched a 20-valent pneumococcal polysaccharide conjugate vaccine in the world, and there are no related products in China. In 2024, Watson Bio achieved revenue of 2.821 billion yuan and net profit attributable to shareholders of the parent company ...
- Source: drugdu
- 158
- April 22, 2025
Flu vaccine started a “price war”, Jindik failed to get out of the loss

In 2024, Jindik achieved operating income of 80.8027 million yuan, a year-on-year decrease of 39.96%, and lost money for the second consecutive year. At present, Jindik has only one product on the market, namely the quadrivalent influenza virus split vaccine. In 2024, the price of this product was reduced by 30%, directly falling below 100 yuan. Profitability was weakened and sales expenses accounted for too high a proportion, both dragging down the company’s performance. In order to get rid of dependence on a single product, Jindik has increased its R&D investment. At present, the rabies vaccine product has completed Phase III clinical trials and is in the process of product registration and declaration. Flu vaccine followed the trend of price reduction, and sales volume and price fell in one year In 2024, Jindik not only failed to reverse the loss, but fell deeper and deeper. On April 17, the company ...
- Source: drugdu
- 130
- April 22, 2025
Kangtai Biological’s revenue in the first quarter of 2025 increased by more than 40% year-on-year, and multiple projects such as the pentavalent vaccine made significant progress

The evening of April 20, Kangtai Biological (300601) released its 2024 annual report and 2025 first quarter report. The company achieved operating income of 2.652 billion yuan in 2024 and a net profit of 246 million yuan attributable to the parent company after deducting non-recurring items; operating income in the first quarter of 2025 was 645 million yuan, a year-on-year increase of 42.85%; net profit attributable to the parent company after deducting non-recurring items was 17 million yuan, a year-on-year increase of 17.56%. The annual report shows that Kangtai Biological’s R&D investment in 2024 was 569 million yuan, accounting for 21.47% of the operating income of the year, and the cumulative R&D investment in the past three years was 2.105 billion yuan, accounting for 22.67% of the cumulative operating income in the past three years. During the reporting period, Kangtai Biological’s new vaccine R&D pipeline has made a number of ...
- Source: drugdu
- 187
- April 21, 2025
The national immunization program will enter a period of dynamic adjustment, and many new vaccines are expected to be included

On the morning of April 19, the 2025 Vaccine and Health Conference was held. Shen Hongbing, deputy director of the National Health Commission and director of the National Disease Control Bureau, shared his outlook and ideas on the future adjustment model of the national immunization program in his speech. Shen Hongbing said that one direction in the future is to dynamically adjust and optimize the national immunization program strategy, and optimize it according to the principles of overall planning, dynamic adjustment, and step-by-step implementation. “We are preparing to make a five-year plan,” he said. The future goal is to gradually narrow the gap between the domestic immunization program and the international level, and gradually include vaccines that need to be included. The last time China substantially included a new vaccine was in 2007. The adjustments in recent years mainly involve vaccination procedures and strategies. Therefore, there is a gap between ...
- Source: drugdu
- 202
- April 21, 2025
Beike Biotech’s revenue and net profit both fell, sales of herpes zoster vaccines decreased, and the core of marketing left

On the evening of April 20, Beike Biotech (688276) released its 2024 annual report showing that during the reporting period, the company’s operating income was approximately 1.229 billion yuan, a year-on-year decrease of 32.64%; the corresponding attributable net profit was approximately 232 million yuan, a year-on-year decrease of 53.67%. It is planned to pay a cash dividend of 1.69 yuan (including tax) per 10 shares to all shareholders. In this regard, the annual report pointed out that the main reason was the decrease in revenue and net profit due to the decrease in sales of herpes zoster vaccines during the reporting period; the net cash flow generated by operating activities was 406.5022 million yuan, 255.2070 million yuan in the same period last year, an increase of 59.28%, mainly due to the increase in sales proceeds; basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring ...
- Source: drugdu
- 195
- April 21, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.